(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 8 January 2004 (08.01.2004)

PCT

(10) International Publication Number WO 2004/002526 A1

(51) International Patent Classification⁷: A61K 39/395, 39/193, 38/20, 38/21

(21) International Application Number:

PCT/EP2003/006591

(22) International Filing Date: 23 June 2003 (23.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/392,311

1 July 2002 (01.07.2002) US

- (71) Applicant (for all designated States except US): WILEX AG [DE/DE]; Grillparzerstrasse 10, 81675 München (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): WARNAAR, Sven, Ole [NL/NL]; Van Beuningenlaan 20, NL-2334 CC Leiden (NL). ULLRICH, Stefan [DE/DE]; Oberfeld 48, 82319 Starnberg (DE).
- (74) Agent: WEICKMANN & WEICKMANN; Postfach 860 820, 81635 München (DE).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CO-ADMINISTRATION OF CG250 AND IL-2 OR IFN-ALPHA FOR TREATING CANCER SUCH AS RENAL CELL CARCINOMAS

(57) Abstract: A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method is characterized in a significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone, resulting in a positive therapeutic response with respect to that observed with single anti-tumor agents alone.

